Cannabis, Cannabidiol, and Epilepsy. Clinical Considerations and Practical Applications. A new frontier brings new questions and old dilemmas. Adrian L. Turner and M. Scott Perry Practical Neurology, October 2018, 31-35 Background As early as 12,000 BCE, texts from central Asia reported human use of cannabis for nonmedical indications including ropes, fibers, and cloth. Ancient Chinese manuscripts from approximately 10,000 years later give the first documented use of cannabis for medical purposes 1. Other early reports from ancient Mesopotamia, Persia, and India describe cannabis use for indications such as spasticity, depression, anxiety, and epilepsy.1,2 Cannabis for medicinal purposes was not scientifically studied until the 19th century. In 1840, [...]
Lire la suiteNeuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals : a Systematic Review A. Batalla, J.A. Crippa, G.F. Busatto, F.S. Guimarães, A.W. Zuardi, O. Valverde, Z. Atakan, P.K. McGuire, S. Bhattacharyya and R. Martín-Santos Current Pharmaceutical Design, 2014, 20, 2168-2185 DOI : 10.2174/13816128113199990432 Available from: https://www.researchgate.net/publication/247154314_Neuroimaging_Studies_of_Acute_Effects_of_THC_and_CBD_in_Humans_and_Animals_a_Systematic_Review [accessed May 19, 2019]. Abstract : Background : In recent years, growing concerns about the effects of cannabis use on mental health have renewed interest in cannabis research. In particular, there has been a marked increase in the number of neuroimaging studies of the effects of cannabinoids. We conducted a systematic review to assess the [...]
Lire la suiteCharacterization of Endocannabinoid-Metabolizing Enzymes in Human Peripheral Blood Mononuclear Cells under Inflammatory Conditions Brittany N. Szafran, Jung Hwa Lee, Abdolsamad Borazjani, Peter Morrison, Grace Zimmerman, Kelly L. Andrzejewski, Matthew K. Ross and Barbara L.F. Kaplan Molecules, 2018, 23, 3167 DOI : 10.3390/molecules23123167 Abstract: Endocannabinoid-metabolizing enzymes are downregulated in response to lipopolysaccharide (LPS) induced inflammation in mice, which may serve as a negative feedback mechanism to increase endocannabinoid levels and reduce inflammation. Increased plasma levels of the pro-inflammatory cytokine interleukin-6 (IL-6) and decreased fatty acid amide hydrolase (FAAH) activity in peripheral lymphocytes from individuals diagnosed with Huntington’s disease (HD) suggests that a similar negative feedback system [...]
Lire la suiteInvestigational Cannabinoids in Seizure Disorders, what have we learned thus far ? Dejana Ružić Zečević, Ziyad Tantoush, Marko Folić, Goran Babić, Milan Radovanović and Slobodan M. Janković may 2018, 23 pages ABSTRACT Introduction : Anticonvulsant activity of cannabinoid attracted much attention in the last decade. Cannabinoids that are currently investigated with intention to become drugs for treatment of epilepsy are cannabidiol, cannabidivarin, Δ9-tetrahydrocannabivarin and Δ9-tetrahydrocannabinolic acid. Areas covered : Topic of this review are results of pre-clinical and clinical studies with investigational cannabinoids. Relevant literature was searched for in MEDLINE, SCOPUS, EBSCO, GOOGLE SCHOLAR and SCINDEX databases. Expert opinion : Pre-clinical studies confirmed anticonvulsant activity of [...]
Lire la suiteCannabinoïde Signaling in the Skin : Therapeutic Potential of the “C(ut)annabinoid” System Kinga Fanni Tóth, Dorottya Ádám, Tamás Bíró, and Attila Oláh Molecules 2019, 24(5), 918; https://doi.org/10.3390/molecules24050918 Abstract : The endocannabinoid system (ECS) has lately been proven to be an important, multifaceted homeostatic regulator, which influences a wide-variety of physiological processes all over the body. Its members, the endocannabinoids (eCBs; e.g., anandamide), the eCB-responsive receptors (e.g., CB1, CB2), as well as the complex enzyme and transporter apparatus involved in the metabolism of the ligands were shown to be expressed in several tissues, including the skin. Although the best studied functions over the ECS are [...]
Lire la suiteA Phase I, Randomized, Double‑Blind, Placebo‑Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects Lesley Taylor,·Barry Gidal,·Graham Blakey, Bola Tayo, Gilmour Morrison CNS Drugs, 2018 https://doi.org/10.1007/s40263-018-0578-5 Abstract Background : A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD, the maximum tolerated dose, and to examine the effect of food on CBD PK parameters. Objective : This trial assessed the safety, tolerability and PK of CBD oral solution in healthy adult volunteers, as well as the effect [...]
Lire la suiteCannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review Jasmine Turna, Sabrina K. Syan, Benicio N. Frey, Brian Rush, Mary Jean Costello, Mark Weiss, and James MacKillop ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 1-14 Abstract : There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified [...]
Lire la suiteCOMMENTARY What's the Standard of Care for Managing Medical Marijuana? Carolyn Buppert, MSN, JD Medscape, April 22, 2019 https://www.medscape.com/viewarticle/911912 A Patient on Medical Marijuana A primary care provider in a state where medical marijuana is legal asked the following question: In my state, an individual can get a recommendation for medical marijuana from a qualified practitioner who has a visit with that person for that reason only. Alternatively, the individual's primary care provider or specialist can recommend it. I have recommended medical marijuana for several of my patients who had conditions qualifying them for medical marijuana. My concern is about my patients who have been qualified for [...]
Lire la suiteThe effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers C. Hindocha, T. P. Freeman, M. Grabski, H. Crudgington, A. C. Davies, J. B. Stroud, R. K. Das, W. Lawn, C. J. A. Morgan & H. V. Curran Scientific Reports, 2018, 8, 7568 DOI:10.1038/s41598-018-25846-2 Abstract : Acute nicotine abstinence in cigarette smokers results in deficits in performance on specific cognitive processes, including working memory and impulsivity which are important in relapse. Cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, has shown pro-cognitive effects and preliminary evidence has indicated it can reduce the number of cigarettes smoked in dependent smokers. However, the effects [...]
Lire la suiteClinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes Ethan B. Russo Cannabis and Cannabinoid Research, 2016, 1, 1, 154-165. DOI: 10.1089/can.2016.0009 Abstract : Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected populations and whose sufferers have all endured the stigma of a psychosomatic label, as well as the failure of endless pharmacotherapeutic interventions with substandard benefit. The commonality in symptomatology in these conditions displaying hyperalgesia [...]
Lire la suite